Tumor-targeted Gd-doped mesoporous Fe3O4 nanoparticles for T1/T2 MR imaging guided synergistic cancer therapy. (1st January 2021)

• Record Type: Journal Article
• Authors: Zheng, Shaohui; Jin, Shang; Jiao, Min; Wang, Wenjun; Zhou, Xiaoyu; Xu, Jie; Wang, Yong; Dou, Peipei; Jin, Zhen; Wu, Changyu; Li, Jingjing; Ge, Xinting; Xu, Kai
• Is Part Of: Drug delivery. Volume 28:Number 1(2021)
• Page Start: 787
• Page End: 799
• Publication Date: 2021-01-01
• Subjects: Tumor targeting -- Gd doping -- mesoporous Fe3O4 NPs -- T1/T2 MR imaging -- synergistic cancer therapy; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2021.1909177
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: In this study, a novel intelligent nanoplatform to integrate multiple imaging and therapeutic functions for targeted cancer theranostics. The nanoplatform, DOX@Gd-MFe3 O4 NPs, was constructed Gd-doped mesoporous Fe3 O4 nanoparticles following with the doxorubicin (DOX) loading in the mesopores of the NPs. The DOX@Gd-MFe3 O4 NPs exhibited good properties in colloidal dispersity, photothermal conversion, NIR triggered drug release, and high T1 /T2 relaxicity rate ( r 1 =9.64 mM −1 s −1, r 2 = 177.71 mM −1 s −1 ). Benefiting from the high MR contrast, DOX@Gd-MFe3 O4 NPs enabled simultaneous T1 /T2 dual-modal MR imagining on 4T1 bearing mice in vivo and the MR contrast effect was further strengthened by external magnetic field. In addition, the DOX@Gd-MFe3 O4 NPs revealed the strongest inhibition to the growth of 4T1 in vitro and in vivo under NIR irradiation and guidance of external magnetic field. Moreover, biosafety was also validated by in vitro and in vivo tests. Thus, the prepared DOX@Gd-MFe3 O4 NPs would provide a promising intelligent nanoplatform for dual-modal MR imagining guided synergistic therapy in cancer theranostics.